United Nations Office on Drugs and Crime. World Drug Report 2019. New York, United Nations Office on Drugs and Crime, 2019.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Luxembourg, Publications Office of the European Union, 2019.Google Scholar

United Nations Office on Drugs and Crime (UNODC). Synthetic Cannabinoids in Herbal Products. New York, United Nations Office on Drugs and Crime, 2011. Available at: www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf [last accessed 24 March 2022].Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Perspectives on Drugs. Synthetic Cannabinoids in Europe. Update 6 June 2017. Available at: www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf [last accessed 26 April 2022].Google Scholar

Winstock, AR, Barratt, MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131(1–3):106–111. https://doi.org/10.1016/j.drugalcdep.2012.12.011CrossRefGoogle Scholar

European Monitoring Centre for Drugs and Drug Addiction. Synthetic Cannabinoids and ‘Spice’ Drug Profile. Available at: www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids [last accessed 24 March 2022].Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Perspectives on Drugs. Synthetic Cannabinoids in Europe. Update 6 June 2017. Available at: https://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf [last accessed 26 April 2022].Google Scholar

Fattore, L, Fratta, W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5:60. https://doi.org/10.3389/fnbeh.2011.00060Google Scholar

Hudson, S, Ramsey, J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011;3:466–478.Google Scholar

Vardakou, I, Pistos, C, Spiliopoulou, C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010;197:157–162.Google Scholar

Loeffler, G, Hurst, D, Penn, A, Yung, K. Spice, bath salts, and the US military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the US Armed Forces. Mil Med 2012;177(9):1041–1048.Google Scholar

Bonaccorso S, Metastasio A, Ricciardi A, et al. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sci 2018;8:133. https://doi.org/10.3390/brainsci8070133Google Scholar

Hudson, S, Ramsey, J, King, L, et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in ‘herbal high’ products. J Anal Toxicol 2010;34(5):252–260.Google Scholar

Huffman, JW, Padgett, LW. Recent developments in the medicinal chemistry of cannabinomimetic indoles, pyrroles and indenes. Curr Med Chem 2005;12:1395–1411.Google Scholar

D’Souza, DC, Perry, E, MacDougall, L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29(8):1558–1572.Google Scholar

Papanti, D, Orsolini, L, Francesconi, G, Schifano, F. ‘Noids’ in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics. Adv Dual Diagn 2014;7(3):1–13.Google Scholar

Zuardi, AW, Crippa, JA, Hallak, JE, Moreira, FA, Guimarães, FS. Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421–429.Google Scholar

Morgan, CJ, Das, RK, Joye, A, Curran, HV, Kamboj, SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013;38(9):2433–2436. https://doi.org/10.1016/j.addbeh.2013.03.011Google Scholar

Murray RM, , Quigley H, , Quattrone D, , Englund A, Di Forti M., Traditional marijuana, high potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 2016;15:195–204.CrossRefGoogle ScholarPubMed

Seely, KA, Prather, PL, James, LP, Moran, JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011;11:36–51.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Synthetic Cannabinoids in Europe (updated 28 May 2013) (Perspectives on Drugs series). EMCDDA, 2013. Available at: www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids [last accessed 24 March 2022].Google Scholar

Huffman, JW, Dai, D, Martin, BR, Compton, DR. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 1994;4:563–566.Google Scholar

Potts AJ, , Cano C, , Thomas SHL, , Hill SL., Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol 2020;58(2):82–98. https://doi.org/10.1080/15563650.2019.1661425CrossRefGoogle ScholarPubMed

Carroll, FI, Lewin, AH, Mascarella, SW, Seltzman, HH, Reddy, PA. Designer drugs: a medicinal chemistry perspective. Ann NY Acad Sci 2012;1248:18–38.Google Scholar

Uchiyama, N, Kawamura, M, Kikura-Hanajiri, R, Goda, Y. Identification and quantitative analyses of two cannabimimetic phenylacetylindoles, JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles, JWH-081, JWH-015, JWH-200 and JWH-073, as designer drugs in illegal products. Forensic Toxicol 2011;29:25–37.Google Scholar

Huffman, J. Cannabimimetic indoles, pyrroles, and indenes: structure–activity relationships and receptor interactions. In: Reggio, PH, (ed.), The Cannabinoid Receptors, pp. 49–94. New York, Humana Press, 2009.Google Scholar

Huffman, JW, Mabon, R, Wu, MJ, et al. 3-indolyl1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 2003;11:539–549.Google Scholar

Auwärter, V, Dresen, S, Weinmann, W, Müller, M, Pütz, M, Ferreirós, N. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009;44(5):832–837. https://doi.org/10.1002/jms.1558Google Scholar

Weissman, A, Milne, GM, Melvin, LS Jr. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 1982;223:516–523.Google Scholar

Devane, WA, Breuer, A, Sheskin, T, Järbe, TU, Eisen, MS, Mechoulam, R. A novel probe for the cannabinoid receptor. J Med Chem 1992;35(11):2065–2069.Google Scholar

Gottardo, R, Chiarini, A, Dal Prà, I, et al. Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J Mass Spectrom 2012;47(1):141–146. https://doi.org/10.1002/jms.2036Google Scholar

Hutter, M, Broecker, S, Kneisel, S, Auwärter, V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom 2012;47(1):54–65. https://doi.org/10.1002/jms.2026Google Scholar

Marusich, JA, Wiley, JL, Lefever, TW, Patel, PR, Thomas, BF. Finding order in chemical chaos – continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology 2018;134(Pt A):73–81. https://doi.org/10.1016/j.neuropharm.2017.10.041Google Scholar

Lindigkeit, R, Boehme, A, Eiserloh, I, et al. Spice: a never-ending story? Forensic Sci Int 2009;191:58–63.Google Scholar

Hermanns-Clausen, M, Kneisel, S, Szabo, B, Auwärter, V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108(3):534–544. https://doi.org/10.1111/j.1360-0443.2012.04078.xGoogle Scholar

Uchiyama, N, Matsuda S, , Kawamura M, , Kikura-Hanajiri, R, Goda Y., Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 2013;31:223–240. https://doi.org/10.1007/s11419-013–0182-9Google Scholar

Adams AJ, , Banister SD, , Irizarry L, , Trecki J, , Schwartz M, , Gerona R, . ‘Zombie’ outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017;376:235–242. https://doi.org/10.1056/NEJMoa1610300Google Scholar

McCain, KR, Jones, JO, Chilbert, KT, Patton, AL, James, LP, Moran, JH. Impaired driving associated with the synthetic cannabinoid 5fAdb. J Forensic Sci Criminol 2018;6(1). https://doi.org/10.15744/2348-9804.6.105Google Scholar

Haden M, , Archer JRH, , Dargan PI, , Wood DM., MDMB-CHMICA: availability, patterns of use, and toxicity associated with this novel psychoactive substance. Subst Use Misuse 2017;52(2):223–232. https://doi.org/10.1080/10826084.2016.1223692Google Scholar

Bilgrei, OR. From ‘herbal highs’ to the ‘heroin of cannabis’: Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum. Int J Drug Policy 2016;29:1–8.Google Scholar

Lamy, FR, Daniulaityte, R, Nahhas, RW, et al. Increases in synthetic cannabinoid-related harms: results from a longitudinal web-based content analysis. Int J Drug Policy 2017;44:121–129. https://doi.org/10.1016/j.drugpo.2017.05.007Google Scholar

Bäckberg, M, Tworek, L, Beck, O, et al. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA Project. J Med Toxicol 2017;13:52–60. https://doi.org/10.1007/s13181-016-0584-2Google Scholar

Advisory Council on the Misuse of Drugs (ACMD). Further Consideration of the Synthetic Cannabinoids. ACMD, October 2012. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/929909/FOR_PUBLICATION_-_ACMD_SCRA_report_final.pdf [last accessed 26 April 2022].Google Scholar

Bäckberg, M, Tworek, L, Beck, O, et al. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA Project. J Med Toxicol 2017;13:52–60. https://doi.org/10.1007/s13181-016-0584-2Google Scholar

See for example www.telegraph.co.uk/news/2017/09/22/letters-sent-prison-photocopied-amid-fears-soaked-drugs/ [last accessed 24 March 2022].Google Scholar

Ford, LT, Berg, JD. Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service. Ann Clin Biochem 2018;55(6);673–678. https://doi.org/10.1177/0004563218767462Google Scholar

Moosmann, B, Angerer, V, Auwärter, V. Inhomogeneities in herbal mixtures: a serious risk for consumers. Forensic Toxicol 2014;33:54–60.CrossRefGoogle Scholar

Choi, H, Heo, S, Choe, S, et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Anal Bioanal Chem 2013;405:3937–3944.Google Scholar

Frinculescu, A, Lyall, CL, Ramsey, J, Miserez, B. Variation in commercial smoking mixtures containing third generation synthetic cannabinoids. Drug Test Anal 2017;9:327–333.Google Scholar

Choi, H, Heo, S, Choe, S, et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Anal Bioanal Chem 2013;405(12):3937–3944. https://doi.org/10.1007/s00216-012-6560-zGoogle Scholar

Ginsburg, BC, McMahon, LR, Sanchez, JJ, Javors, MA. Purity of synthetic cannabinoids sold online for recreational use. J Anal Toxicol 2012;36(1):66–68. https://doi.org/10.1093/jat/bkr018Google Scholar

Brandt, SD, Sumnall, HR, Measham, F, Cole, J. Analyses of second-generation ‘legal highs’ in the UK: initial findings. Drug Test Anal 2010;2:377–382.Google Scholar

Brandt, SD, Sumnall, HR, Measham, F, Cole, J. Second generation mephedrone: the confusing case of NRG-1. Br Med J 2010;341:c3564.Google Scholar

Davies, S, Wood, DM, Smith, G, et al. Purchasing ‘legal highs’ on the Internet – is there consistency in what you get? QJM 2010;103:489–493.Google Scholar

Ramsey, J, Dargan, PI, Smyllie, M, et al. Buying ‘legal’ recreational drugs does not mean that you are not breaking the law. QJM 2010;103:777–783.Google Scholar

Hillebrand, J, Olszewski, D, Sedefov, R. Legal highs on the Internet. Subst Use Misuse 2010;45:330–340.CrossRefGoogle ScholarPubMed

Pintori, N, Loi, B, Mereu, M. Synthetic cannabinoids: the hidden side of spice drugs. Behav Pharmacol 2017;28:409–419.Google Scholar

World Health Organization (WHO). JWH-018. Critical Review Report Agenda Item 4.5. Expert Committee on Drug Dependence 36th Meeting, Geneva, 16–20 June 2014.Google Scholar

Abouchedid, R, Hudson, S, Thurtle, N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an emergency department in London, UK in the first half of 2015. Clin Toxicol 2017;55:338–345.Google Scholar

Kikura-Hanajiri, R, Uchiyama, N, Kawamura, M, et al. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 2013;31:44–53.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850–1861.Google Scholar

Ogata, J, Uchiyama, N, Kikura-Hanajiri, R, Goda, Y. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic Sci Int 2013;227(1–3):33–41.Google Scholar

Uchiyama, N, Matsuda, S, Kawamura, M, Kikura-Hanajiri, R, Goda, Y. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 2013;31:223–240.Google Scholar

Lonati, D, Buscaglia, E, Papa, P, et al. MAM-2201 (analytically confirmed) intoxication after ‘Synthacaine’ consumption. Ann Emerg Med 2014;64(6):629–632. https://doi.org/10.1016/j.annemergmed.2014.01.007Google Scholar

Uchiyama, N, Kawamura, M, Kikura-Hanajiri, R, Goda, Y. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 2013;227(1–3):21–32.Google Scholar

Wurita, A, Hasegawa, K, Minakata, K, Watanabe, K, Suzuki, O. A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product. Forensic Toxicol 2014;32(2):331–337.Google Scholar

Park, Y, Lee, C, Lee, H, et al. Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-ethoxybenzoyl) indole. Forensic Toxicol 2013;31:187–196.Google Scholar

Uchiyama, N, Shimokawa, Y, Matsuda, S, Kawamura, M, Kikura-Hanajiri, R, Goda, Y. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 2014;32(1):105–115.Google Scholar

Uchiyama, N, Kikura-Hanajiri, R, Ogata, J, Goda, Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010;198:31–38.Google Scholar

Zuba, D, Byrska, B, Maciow, M. Comparison of ‘herbal highs’ composition. Anal Bioanal Chem 2011;400:119–126.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Synthetic Cannabinoids and ‘Spice’ Drug Profile. Available at: www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids [last accessed 24 March 2022].Google Scholar

Dresen, S, Ferreirós, N, Pütz, M, Westphal, F, Zimmermann, R, Auwärter, V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010;45(10):1186–1194. https://doi.org/10.1002/jms.1811Google Scholar

Simmons, J, Cookman, L, Kang, C, Skinner, C. Three cases of ‘spice’ exposure. Clin Toxicol 2011;49:431–433.Google Scholar

Simmons, JR, Skinner, CG, Williams, J, Kang, CS, Schwartz, MD, Wills, BK. Intoxication from smoking ‘Spice’. Ann Emerg Med 2011;57:187–188.Google Scholar

Seely, KA, Lapoint, J, Moran, JH, Fattore, L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012;39(2):234–243. https://doi.org/10.1016/j.pnpbp.2012.04.017Google Scholar

Castellanos, D, Thornton, G. Synthetic cannabinoid use: recognition and management. J Psychiatr Pract 2012;18(2):86–93. https://doi.org/10.1097/01.pra.0000413274.09305.9cGoogle Scholar

Dargan, PI, Hudson, S, Ramsey, J, Wood, DM. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in ‘Spice’. Int J Drug Policy 2011;22(4):274–277. https://doi.org/10.1016/jdrugpo.2011.02.006.CrossRefGoogle ScholarPubMed

Adams, AJ, Banister, SD, Irizarry, L, Trecki, J, Schwartz, M, Gerona, R. ‘Zombie’ outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017;376:235–242.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. New Psychoactive Substances in Europe: An Update from the EU Early Warning System. 2015. Available at: www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf [last accessed 26 April 2022].Google Scholar

United Nations Office on Drugs and Crime. World Drug Report 2016. Available at: https://www.unodc.org/LSS/Home/BothAreas [last accessed 26 April 2022].Google Scholar

Van Amsterdam, J, Nutt, D, van den Brink, W. Generic legislation of new psychoactive drugs. J Psychopharmacol 2013;27(3):317–324.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Perspectives on Drugs. Synthetic Cannabinoids in Europe. Available at: www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf [last accessed 26 March 2022].Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Luxembourg, Publications Office of the European Union, 2019.Google Scholar

HM Inspectorate of Prisons. HM Chief Inspector of Prisons for England and Wales: Annual Report 2013–2014.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report: Trends and Developments. Luxembourg, Publications Office of the European Union, 2018.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Perspective on Drugs: Synthetic Cannabinoids in Europe. Luxembourg, Publications Office of the European Union, 2017.Google Scholar

Akram, H, Mokrysz, C, Curran, HV. What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol 2019;33(3):271–283. https://doi.org/10.1177/0269881119826592CrossRefGoogle ScholarPubMed

Smith, KE, Staton, M. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: are synthetic cannabinoids actually preferred to other drugs? Subst Abuse 2018;40(2):1–10. https://doi.org/10.1080/08897077.2018.1528495Google ScholarPubMed

Mathews, EM, Jeffries, E, Hsieh, C, Jones, G, Buckner, JD. Synthetic cannabinoid use among college students. Addict Behav 2019;93:219–224. https://doi.org/10.1016/j.addbeh.2019.02.009Google Scholar

Vandrey, R, Dunn, KE, Fry, JA, Girling, ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012;120(1–3):238–241. https://doi.org/10.1016/j.drugalcdep.2011.07.011Google Scholar

Barratt, MJ, Cakic, V, Lenton, S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013;32(2):141–146. https://doi.org/10.1111/j.1465-3362.2012.00519.xCrossRefGoogle ScholarPubMed

Castellanos, D, Singh, S, Thornton, G, Avila, M, Moreno, A. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011;49(4):347–349.Google Scholar

Hurst, D, Loeffler, G, McLay, R. Synthetic cannabinoid agonist induced psychosis: a case series. APA poster. San Diego, Naval Medical Centre, 2011. Abstract in Am J Psychiatry 2011;168(10):1119. https://doi.org/10.1176/appi.ajp.2011.11010176).Google Scholar

Van Der Veer, N, Friday, J. Persistent psychosis following the use of Spice. Schizophrenia Res 2011;130:285–286.Google Scholar

Peglow, S, Buchner, J, Briscoe, G. Synthetic cannabinoid-induced psychosis in a previously nonpsychotic patient. Am J Addict 2012;21:287–288.Google Scholar

Tung, CK, Chiang, TP, Lam, M. Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry 2012;22(1):31–33.Google Scholar

Chan, WL, Wood, DM, Hudson, S, Dargan, PI. Acute psychosis associated with recreational use of benzofuran 6-(2 aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol 2013;9(3):278–281. https://doi.org/10.1007/s13181-013-0306-yGoogle Scholar

Thornton, SL, Lo, J, Clark, RF, Wu, AH, Gerona, RR. Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis. Clin Toxicol 2012;50(10):1165–1168. https://doi.org/10.3109/15563650.2012.744996Google Scholar

Abouchedid, R, Ho, JH, Hudson, S, et al. Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol 2016;12(4):396–401. https://doi.org/10.1007/s13181-016-0571-7CrossRefGoogle ScholarPubMed

Abouchedid, R, Ho, JH, Hudson, S, et al. Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol 2016;12(4):396–401. https://doi.org/10.1007/s13181-016-0571-7Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Understanding the Spice Phenomenon. EMCDDA, 2009.Google Scholar

Brents, LK, Prather, PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 2014;46(1):72–85. https://doi.org/10.3109/03602532.2013.839700Google Scholar

Johnson, LA, Johnson, RL, Portier, RB. Current ‘legal highs’. J Emerg Med 2013;44(6):1108–1115. https://doi.org/10.1016/j.jemermed.2012.09.147Google Scholar

Van Hout, MC, Hearne, E. User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes. Int J Ment Health Addict 2017;15(3):565–579.CrossRefGoogle Scholar

Schifano, F, Corazza, O, Deluca, P, et al. Psychoactive drug or mystical incense? Overview of the online available information on spice products. Int J Cult Ment Health 2009;2:137–144.Google Scholar

Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use: multiple states. Morb Mort Wkly Rep 2013;62(6):93–98.Google Scholar

Bebarta, VS, Ramirez, S, Varney, SM. Spice: a new ‘legal’ herbal mixture abused by young active-duty military personnel. Subst Abuse 2012;33:191–194.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Luxembourg, Publications Office of the European Union, 2019.Google Scholar

Ellsworth, JT. Spice, vulnerability, and victimization: synthetic cannabinoids and interpersonal crime victimization among homeless adults [published online ahead of print, 7 November 2019]. Subst Abus 2019;2019:1–7. https://doi.org/10.1080/08897077.2019.1686725CrossRefGoogle Scholar

Advisory Council on the Misuse of Drugs (ACMD). Benzofurans: A Review of the Evidence of Use and Harm. ACMD, November 2013.Google Scholar

Ralphs, R, Williams, L, Askew, R, Norton, A. Adding Spice to the Porridge: the development of a synthetic cannabinoid market in an English prison. Int J Drug Policy 2017;40:57–69.Google Scholar

Walker, DF. The informal economy in prison. Crim Justice Matters 2015;99(1):18–19.Google Scholar

User Voice: Spice: The Bird Killer. What Prisoners Think about the Use of Spice and Other Legal Highs in Prison. Published May 2016. Available at: www.uservoice.org/wp-content/uploads/2020/07/User-Voice-Spice-The-Bird-Killer-Report-compressed.pdf [last accessed 26 April 2022].Google Scholar

Forrester, M, Kleinschmidt, K, Schwarz, E, Young, A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 2012;31:1006–1011.Google Scholar

Schifano, F, Deluca, P, Baldacchino, A, et al. Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:640–646.Google Scholar

Teske, J, Weller, JP, Fieguth, A, Rothämel, T, Schulz, Y, Tröger, HD. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl) methanone (JWH-018) in human serum by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2659–2663.Google Scholar

Mathews, EM, Jeffries, E, Hsieh, C, Jones, G, Buckner, JD. Synthetic cannabinoid use among college students. Addict Behav 2019;93:219–224. https://doi.org/10.1016/jaddbeh.2019.02.009.Google Scholar

Smith, KElin, Staton, M. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: are synthetic cannabinoids actually preferred to other drugs? Subst Abuse 2018;2018:1–10. https://doi.org/10.1080/08897077.2018.1528495Google Scholar

Shanks, KG, Dahn, T, Terrell, AR. Detection of JWH-018 and JWH-073 by UPLC–MS-MS in postmortem whole blood casework. J Analytical Toxicol 2012;36:145–152.CrossRefGoogle ScholarPubMed

Saito, T, Namera, A, Miura, N, et al. A fatal case of MAM-2201 poisoning. Forensic Toxicol 2013;31:333–337.Google Scholar

Kronstrand, R, Roman, M, Andersson, M, Eklund, A. Toxicological findings of synthetic cannabinoids in recreational users. J Analytical Toxicol 2013;37(8):534–541.CrossRefGoogle ScholarPubMed

Schaefer, N, Peters, B, Bregel, D, et al. A fatal case involving several synthetic cannabinoids. Toxichem Krimtech 2013;80(special issue):248.Google Scholar

Behonick, G, Shanks, KG, Firchau, DJ, et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 2014;38(8):559–562. https://doi.org/10.1093/jat/bku048Google Scholar

Savasman, CM, Peterson, DC, Pietak, BR, Dudley, MH, Clinton Frazee, III C, Garg, U. Two fatalities due to the use of synthetic cannabinoids alone. In: Proceedings of the 66th Annual Scientific Meeting of the American Academy of Forensic Sciences, Seattle, WA 17–22 February, 2014, p. 316. Denver, CO, Publication Printers, 2014.Google Scholar

Corkery, J, Claridge, H, Loi, B, Goodair, C, Schifano, F. NPSAD Annual Report 2013 – Drug-Related Deaths in the UK: January–December 2012. National Programme on Substance Abuse Deaths (NPSAD), 2014.Google Scholar

Elliott, S, Evans, J. A 3-year review of new psychoactive substances in casework. Forensic Sci Int 2014;243:55–60.Google Scholar

Wikstrom, M, Thelander, G, Dahlgren, M, Kronstrand, R. An accidental fatal intoxication with methoxetamine. J Analytic Toxicol 2013;37(1):43–46.Google Scholar

Rosenbaum, CD, Scalzo, AJ, Long, C, et al. K2 and Spice abusers: a case series of clinical and laboratory findings. Paper presented at the North American Congress of Clinical Toxicology (NACCT), 21–26 September, Washington, DC, 2011.Google Scholar

Patton, AL, Chimalakonda, KC, Moran, CL, et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 2013;58(6):1676–1680. https://doi.org/10.1111/1556-4029.12216Google Scholar

Reports to PHE’s Drug Alerts, March 2018.Google Scholar

Report to PHE by Manchester Local Drug Information System ‘Spice Warning,’ August 2018.Google Scholar

Shanks, KG, Behonick, GS. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int 2016;262:e21–e24.Google Scholar

Somerville, RF, Hassan, VR, Kolbe, E, et al. The identification and quantification of synthetic cannabinoids seized in New Zealand in 2017. Forensic Sci Int 2019;300:19–27.Google Scholar

Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol 2019 (online). https://doi.org/10.1080/15563650.2019.1647344Google Scholar

Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol 2019 (online). https://doi.org/10.1080/15563650.2019.1647344CrossRefGoogle Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2016;54(1):1–13.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System (June 2018). Luxembourg, Publications Office of the European Union, 2018.Google Scholar

Fattore, L, Fratta, W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5:60.Google Scholar

Seely, KA, Prather, PL, James, LP, et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011;11:36–51.Google Scholar

Mills, B, Yepes, A, Nugent, K. Synthetic cannabinoids. Am J Med Sci 2015;350(1): 59–62.Google Scholar

Harris, CR, Brown, A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013;44(2):360–366. https://doi.org/10.1016/j.jemermed.2012.07.061Google Scholar

Akram, H, Mokrysz, C, Curran, HV. What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol 2019;33(3):271–283.  https://doi.org/10.1177/0269881119826592CrossRefGoogle ScholarPubMed

Albertson, TE, Chenoweth, JA, Colby, DK, et al. The changing drug culture: medical and recreational marijuana. FP Essent 2016;441:11–17.Google Scholar

D’Souza, DC, Radhakrishnan, R, Sherif, M, et al. Cannabinoids and psychosis. Curr Pharm Des 2016;22(42):6380–6391.Google ScholarPubMed

Gray, R, Bressington, D, Hughes, E, et al. A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness. J Psychiatr Ment Health Nurs 2016;23(5):267–281.CrossRefGoogle ScholarPubMed

Van Amsterdam, J, Brunt, T, van den Brink, W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29(3): 254–263.Google Scholar

White CM., The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol 2017;57(3):297–304.CrossRefGoogle ScholarPubMed

Banister, SD, Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins. Handb Exp Pharmacol 2018;252:165–190.  https://doi.org/10.1007/164_2018_143Google Scholar

Zaurova, M, Hoffman, RS, Vlahov, D, Manini, AF. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol 2016;12(4):335–340. https://doi.org/10.1007/s13181-016-0558-4Google Scholar

Mensen VT, , Vreeker A, , Nordgren J, et al. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology 2019;236:2677–2685. https://doi.org/10.1007/s00213-019-05238-8Google Scholar

Bassir Nia, A, Medrano, B, Perkel, C, et al. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol 2016;30(12):1321–1330.Google Scholar

Bassir Nia, A, Medrano, B, Perkel, C, et al. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol 2016;30(12):1321–1330.Google Scholar

Shalit, N, Barzilay, R, Shoval, G, et al. Characteristics of synthetic cannabinoid and cannabis users admitted to a psychiatric hospital: a comparative study. J Clin Psychiatry 2016;77(8):e989–e995. https://doi.org/10.4088/JCP.15m09938Google Scholar

Mathews, EM, Jeffries, E, Hsieh, C, Jones, G, Buckner, JD. Synthetic cannabinoid use among college students. Addict Behav 2019;93:219–224. https://doi.org/10.1016/jaddbeh.2019.02.009.CrossRefGoogle ScholarPubMed

Winstock, AR, Barratt, MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131(1–3):106–111. https://doi.org/10.1016/j.drugalcdep.2012.12.011Google Scholar

Winstock, AR, Barratt, MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013;28(4):390–393. https://doi.org/10.1002/hup.2292Google Scholar

Hoyte, CO, Jacob, J, Monte, AA, Al-Jumaan, M, Bronstein, AC, Heard, KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012;60:435–438.Google Scholar

Winstock, AR, Barratt, MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131(1–3):106–111. https://doi.org/10.1016/j.drugalcdep.2012.12.011Google Scholar

Winstock, AR, Barratt, MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013;28(4):390–393. https://doi.org/10.1002/hup.2292Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2016;54(1):1–13.Google Scholar

Cooper, ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18:52. https://doi.org/10.1007/s11920-016-0694-11Google Scholar

Advisory Council on the Misuse of Drugs. ‘Third Generation’ Synthetic Cannabinoids. ACMD, 2014.Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2016;54(1):1–13.Google Scholar

Karila, L, Roux, P, Rolland, B, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des 2014;20:4112–4118.CrossRefGoogle ScholarPubMed

Schneir, AB, Cullen, J, Ly, BT. ‘Spice’ girls: synthetic cannabinoid intoxication. J Emerg Med 2011;40:296–299.Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2016;54(1):1–13.Google Scholar

Lovett, C, Wood, DM, Dargan, PI. Pharmacology and toxicology of the synthetic cannabinoid receptor agonists. Réanimation 2015;24:527–541.CrossRefGoogle Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850–1861.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Law, R, Schier, J, Martin, C, et al.Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use in the United States, January to May 2015. Morb Mort Wkly Rep 2015;64(22):618 e619 .Google ScholarPubMed

Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use: multiple states, 2012. Morb Mort Wkly Rep 2013;62(6):93–98.Google Scholar

Murphy, TD, Weidenbach, KN, Houten, CV, et al. Acute kidney injury associated with synthetic cannabinoid use: multiple states, 2012. Morb Mort Wkly Rep 2013;62:93–98.Google Scholar

Schwartz, MD, Trecki, J, Edison, LA, Steck, AR, Arnold, JK, Gerona, RR. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 2015;48:573–580.Google Scholar

Tyndall, JA, Gerona, R, De Portu, G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol 2015;53:950–956.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Adams, AJ, Banister, SD, Irizarry, L, Trecki, J, Schwartz, M, Gerona, R. ‘Zombie’ outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017;376:235–242.CrossRefGoogle ScholarPubMed

Abouchedid, R, Ho, JH, Hudson, S, et al. Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol 2016;12(4):396–401. https://doi.org/10.1007/s13181-016-0571-7Google Scholar

Ross, CH, Singh, P, Simon, EL. Hemorrhagic soft tissue upper airway obstruction from brodifacoum-contaminated synthetic cannabinoid. J Emerg Med 2019;57(1):47–50.Google Scholar

Kelkar, AH, Smith, NA, Martial, A, Moole, H, Tarantino, MD, Roberts, JC. An outbreak of synthetic cannabinoid–associated coagulopathy in Illinois. N Engl J Med 2018;379:1216–1223. https://doi.org/10.1056/NEJMoa1807652Google Scholar

See for example, Hasan O, Patel AA, Siegert JJ. A new differential diagnosis: synthetic cannabinoid-associated gross hematuria. Case Rep Med 2019;2019:6327819. https://doi.org/10.1155/2019/6327819Google Scholar

Riley, SB, Sochat, M, Moser, K, et al. Case of brodifacoum-contaminated synthetic cannabinoid. Clin Toxicol 2019;57(2):143–144. https://doi.org/10.1080/15563650.2018.1502444Google Scholar

Chan, A, Adashek, M, Kang, J, Medinab, AJ. Disseminated intravascular coagulopathy secondary to unintentional brodifacoum poisoning via synthetic marijuana. Hematol 2019;8(1):40–43.Google Scholar

Cooper ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18:52. https://doi.org/10.1007/s11920-016-0694-1Google Scholar

Tournebize, J, Gibaja, V, Kahn, JP. Acute effects of synthetic cannabinoids: update 2015. Subst Abuse 2017;38(3):344–366. https://doi.org/10.1080/08897077.2016.1219438Google Scholar

Sud, P, Gordon, M, Tortora, L, et al. Retrospective chart review of synthetic cannabinoid intoxication with toxicologic analysis. West J Emerg Med 2018;19(3):567–572. https://doi.org/10.5811/westjem.2017.12.36968Google Scholar

Centers for Disease Control and Prevention (CDC). Notes from the field: severe illness associated with reported use of synthetic marijuana – Colorado, August to September 2013. Morb Mort Wkly Rep 2013;62(49):1016e1017.Google Scholar

Drenzek, C, Geller, RJ, Steck, A. Notes from the field: severe illness associated with synthetic cannabinoid use –Brunswick, Georgia, 2013. Morb Mort Wkly Rep 2013;62(46):939.Google Scholar

Kasper, AM, Ridpath, AD, Arnold, JK, et al. Notes from the field: severe illness associated with reported use of synthetic cannabinoids –Mississippi, April 2015. Morb Mort Wkly Rep 2015;64(39):1121–1122.CrossRefGoogle Scholar

Law, R, Schier, J, Martin, C, et al. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use – United States, January–May 2015. Morb Mort Wkly Rep 2015;64(22):618–619.Google Scholar

Springer YP, Gerona R, Scheunemann E, et al. Increase in adverse reactions associated with use of synthetic cannabinoids – Anchorage, Alaska, 2015–2016. Morb Mortal Wkly Rep 2016;65:1108e1111.Google Scholar

Abouchedid, R, Hudson, S, Thurtle, N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an emergency department in London, UK in the first half of 2015. Clin Toxicol 2017;55(5):338–345. https://doi.org/10.1080/15563650.2017.1287373Google Scholar

Hill, SL, Najafi, J, Dunn, M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoids MDMBCHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol 2016;54:638–643.Google Scholar

Hill, SL, Najafi, J, Dunn, M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoids MDMBCHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol 2016;54:638–643.CrossRefGoogle ScholarPubMed

Gugelmann, H, Gerona, R, Li, C, et al. ‘Crazy Monkey’ poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol 2014;52:635–638.Google Scholar

Zaurova, M, Hoffman, RS, Vlahov, D, Manini, AF. clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol 2016;12(4):335–340. https://doi.org/10.1007/s13181-016-0558-4Google Scholar

Sud, P, Gordon, M, Tortora, L, et al. Retrospective chart review of synthetic cannabinoid intoxication with toxicologic analysis. West J Emerg Med 2018;19(3):567–572. https://doi.org/10.5811/westjem.2017.12.36968Google Scholar

Compton, DR, Johnson, MR, Melvin, LS, Martin, BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992;260(1):201–209.Google Scholar

D’Ambra, TE, Estep, KG, Bell, MR, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992;35(1):124–135.Google Scholar

Sud, P, Gordon, M, Tortora, L, et al. Retrospective chart review of synthetic cannabinoid intoxication with toxicologic analysis. West J Emerg Med 2018;19(3):567–572. https://doi.org/10.5811/westjem.2017.12.36968CrossRefGoogle ScholarPubMed

De Brabanter, N, Deventer, K, Stove, V, Van Eenoo, P. Synthetic cannabinoids: general considerations. P Belg Roy Acad Med 2013;2:209–225.Google Scholar

Wiley, JL, Marusich, JA, Huffman, JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci 2014;97(1):55–63. https://doi.org/10.1016/j.lfs.2013.09.011Google Scholar

Halberstadt, AL, Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011;61(3):364–381.CrossRefGoogle Scholar

Wells, DL, Ott, CA. The new marijuana. Ann Pharmacother 2011;45(3):414–417.Google Scholar

Yip, L, Dart, RC. Is there something more about synthetic cannabinoids? Forensic Toxicol 2014;32(2):340–341.Google Scholar

Fisar, Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 2010;381(6):563–572. https://doi.org/10.1007/s00210-010-0517-6Google Scholar

Bonaccorso S, , Metastasio A, , Ricciardi A, et al. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sci 2018;8:133. https://doi.org/10.3390/brainsci8070133Google Scholar

Zarifi, C, Vyas, S. Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. Perm J 2017;21:16–160. https://doi.org/10.7812/TPP/16-160Google Scholar

Tournebize, J, Gibaja, V, Kahn, JP. Acute effects of synthetic cannabinoids: update 2015. Subst Abuse 2017;38(3):344–366. https://doi.org/10.1080/08897077.2016.1219438Google Scholar

Sud, P, Gordon, M, Tortora, L, et al. Retrospective chart review of synthetic cannabinoid intoxication with toxicologic analysis. West J Emerg Med 2018;19(3):567–572. https://doi.org/10.5811/westjem.2017.12.36968Google Scholar

Centers for Disease Control and Prevention (CDC). Notes from the field: severe illness associated with reported use of synthetic marijuana – Colorado, August–September 2013. Morb Mort Wkly Rep 2013;62(49):1016e1017.Google Scholar

Drenzek, C, Geller, RJ, Steck, A. Notes from the field: severe illness associated with synthetic cannabinoid use – Brunswick, Georgia, 2013. Morb Mort Wkly Rep 2013;62(46):939.Google Scholar

Kasper, AM, Ridpath, AD, Arnold, JK, et al. Notes from the field: severe illness associated with reported use of synthetic cannabinoids – Mississippi, April 2015. Morb Mort Wkly Rep 2015;64(39):1121e1122.Google Scholar

Law, R, Schier, J, Martin, C, et al. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use – United States, January–May 2015. Morb Mort Wkly Rep 2015;64(22):618e619.Google Scholar

Springer, YP, Gerona, R, Scheunemann, E, et al. Increase in adverse reactions associated with use of synthetic cannabinoids – Anchorage, Alaska, 2015e2016. Morb Mort Wkly Rep 2016;65:1108e1111.Google Scholar

Hill, SL, Najafi, J, Dunn, M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoids MDMBCHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol 2016;54:638–643.Google Scholar

Gugelmann, H, Gerona, R, Li, C, et al. ‘Crazy Monkey’ poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol 2014;52:635–638.Google Scholar

Karila, L, Roux, P, Rolland, B, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des 2014;20:4112–4118.CrossRefGoogle ScholarPubMed

Abouchedid, R, Hudson, S, Thurtle, N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an emergency department in London, UK in the first half of 2015. Clin Toxicol 2017;55(5):338–345. https://doi.org/10.1080/15563650.2017.1287373Google Scholar

Schneir, AB, Cullen, J, Ly, BT . ‘Spice’ girls: synthetic cannabinoid intoxication. J Emerg Med 2011;40:296–299.Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Lovett, C, Wood, DM, Dargan, PI. Pharmacology and toxicology of the synthetic cannabinoid receptor agonists. Réanimation 2015;24:527–541.Google Scholar

McQuade, D, Hudson, S, Dargan, PI, Wood, DM. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 2013;69:373–376. https://doi.org/10.1007/s00228-012-1379-2Google Scholar

Papanti, D, Schifano, F, Botteon, G, et al. ‘Spiceophrenia’: a systematic overview of ‘spice’-related psychopathological issues and a case report. Hum Psychopharmacol 2013;28(4):379–389. https://doi.org/10.1002/hup.2312CrossRefGoogle ScholarPubMed

Spaderna, M, Addy, P, D’Souza, DC. Spicing things up: synthetic cannabinoids. Psychopharmacology 2013;228(4):525–540.Google Scholar

Winstock, AR, Barratt, MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013;28(4):390–393. https://doi.org/10.1002/hup.2292Google Scholar

Freeman, MJ, Rose, DZ, Myers, MA, Gooch, CL, Bozeman, AC, Burgin, WS. Ischemic stroke after use of the synthetic marijuana ‘spice’. Neurology 2013;81(24):2090–2093.Google Scholar

Mir, A, Obafemi, A, Young, A, Kane, C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011;128(6):e1622–1627.Google Scholar

Zimmermann, US, Winkelmann, PR, Pilhatsch, M, Nees, JA, Spanagel, R, Schulz, K. Withdrawal phenomena and dependence syndrome after the consumption of ‘Spice Gold’. Dtsch Arztebl Int 2009;106(27):464–467. https://doi.org/10.3238/arztebl.2009.0464Google Scholar

Banerji, S, Deutsch, CM, Bronstein, AC. Spice ain’t so nice. Clin Toxicol 2010;48:632(abstract 137). Available at: http://informahealthcare.com/doi/pdf/10.3109/15563650.2010.493290 [last accessed 27 March 2022].Google Scholar

Every-Palmer, S. Warning: legal synthetic cannabinoid receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010;105:1959–1960.Google Scholar

Johnson, LA, Johnson, RL, Alfonzo, C. Spice: a legal marijuana equivalent. Mil Med 2011;176:718–720.Google Scholar

Benford, DM, Caplan, JP. Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 2011;52:295.Google Scholar

Vearrier, D, Osterhoudt, KC. A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 2010;26:462–465.Google Scholar

Donnelly MT. Health Advisory: K2 Synthetic Marijuana Use Among Teenagers and Young Adults in Missouri. Missouri Department of Health and Senior Services, 5 March 2010. Available at: http://health.mo.gov /emergencies/ert/alertsadvisories/pdf/HAd3-5-2010.pdf [last accessed 27 March 2022].Google Scholar

Cohen, K, Kapitány-Fövény, M, Mama, Y, et al. The effects of synthetic cannabinoids on executive function. Psychopharmacology 2017;234(7):1121–1134. https://doi.org/10.1007/s00213-017-4546-4Google Scholar

Theunissen, EL, Hutten, NR, Mason, NL, et al. Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study. Br J Pharmacol 2018;175(1):18–28.Google Scholar

Schneir, AB, Cullen, J, Ly, BT. ‘Spice’ girls: synthetic cannabinoid intoxication. J Emerg Med 2011;40(3):296–299. https://doi.org/10.1016/j.jemermed.2010.10.014Google Scholar

Every-Palmer, S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011;117:152–157.Google Scholar

Müller, H, Sperling, W, Köhrmann, M, et al. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis-induced recurrent psychotic episodes. Schizophr Res 2010;118:309–310.Google Scholar

Young, AC, Schwarz, E, Medina, G, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012;30(7):1320.e5–7. https://doi.org/10.1016/j.ajem.2011.05.013Google Scholar

Thomas, S, Bliss, S, Malik, M. Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc 2012;105(11):430–433.Google Scholar

Pierre, JM. Cannabis, synthetic cannabinoids, and psychosis risk: what the evidence says. Curr Psychiatr 2011;10:49–58.Google Scholar

Hobbs, M, Kalk, NJ, Morrison, PD, Stone, J. Spicing it up: synthetic cannabinoid receptor agonists and psychosis: a systematic review. Eur Neuropsychopharmacol 2018;28(12):1289–1304. https://doi.org/10.1016/j.euroneuro.2018.10.004Google Scholar

Shafi, A, Gallagher, P, Stewart, N, Martinotti, G, Corazza, O. The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services. Hum Psychopharmacol 2017;32:3.Google Scholar

Akram, H, Mokrysz, C, Curran, HV. What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol 2019;33(3):271–283. https://doi.org/10.1177/0269881119826592Google Scholar

Cohen, K, Weinstein, AM. Synthetic and non-synthetic cannabinoid drugs and their adverse effects: a review from a public health perspective. Front Public Health 2018;7(6):162.Google Scholar

Papanti, D, Schifano, F, Botteon, G, et al. ‘Spiceophrenia’: a systematic overview of ‘Spice’‐related psychopathological issues and a case report. Hum Psychopharmacol Clin Exp 2013;28(4):379–389.Google Scholar

Karila, L, Benyamina, A, Blecha, L, Cottencin, O, Billieux, J. The synthetic cannabinoids phenomenon. Curr Pharm Des 2016;22(42):6420–6425.Google Scholar

Cohen, K, Kapitány-Fövény, M, Mama, Y, et al. The effects of synthetic cannabinoids on executive function. Psychopharmacology 2017;234(7):1121–1134. https://doi.org/10.1007/s00213-017-4546-4Google Scholar

Clayton, HB, Lowry, R, Ashley, C, et al. Health risk behaviors with synthetic cannabinoids versus marijuana. Pediatrics 2017;139(4):e20162675.Google Scholar

Müller, HH, Kornhuber, J, Sperling, W. The behavioral profile of spice and synthetic cannabinoids in humans. Brain Res Bull 2016;126:3–7.Google Scholar

Van Der Veer, N, Friday, J. Persistent psychosis following the use of Spice. Schizophr Res 2011;130(1):285–286.Google Scholar

Pereira, LE, Toteja, N, Khizar, A, et al.Effect of synthetic cannabinoids and natural cannabis on severity of psychotic symptoms and aggression in adolescents and young adults with psychosis in an inpatient setting. J Am Acad Child Adolesc Psychiatry 2016;55(10):235–236.Google Scholar

Shalit, N, Barzilay, R, Shoval, G, et al. Characteristics of synthetic cannabinoid and cannabis users admitted to a psychiatric hospital: a comparative study. J Clin Psychiatry 2016;77(8):989–995.Google Scholar

Wilkinson, ST, Radhakrishnan, R, D’Souza, DC. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep 2014;1(2):115–128.Google Scholar

Brakoulias, V. Products containing synthetic cannabinoids and psychosis. Aust NZ J Psychiatry 2012;46(3):281–282. https://doi.org/10.1177/0004867411433974Google Scholar

Hobbs, M, Kalk, NJ, Morrison, PD, Stone, JM. Spicing it up – synthetic cannabinoid receptor agonists and psychosis – a systematic review. Eur Neuropsychopharmacol 2018;28(12):1289–1304. https://doi.org/10.1016/j.euroneuro.2018.10.004Google Scholar

Morgan, CJ, Schafer, G, Freeman, TP, Curran, HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010;197(4):285–290. https://doi.org/10.1192/bjp.bp.110.077503Google Scholar

Hobbs, M, Kalk, NJ, Morrison, PD, Stone, JM. Spicing it up – synthetic cannabinoid receptor agonists and psychosis – a systematic review. Eur Neuropsychopharmacol 2018;28(12):1289–1304. https://doi.org/10.1016/j.euroneuro.2018.10.004Google Scholar

Pereira, LE, Toteja, N, Khizar, A, et al.Effect of synthetic cannabinoids and natural cannabis on severity of psychotic symptoms and aggression in adolescents and young adults with psychosis in an inpatient setting. J Am Acad Child Adolesc Psychiatry 2016;55(10):235–236.Google Scholar

Shalit, N, Barzilay, R, Shoval, G, et al. Characteristics of synthetic cannabinoid and cannabis users admitted to a psychiatric hospital: a comparative study. J Clin Psychiatry 2016;77(8):989–995.Google Scholar

Coppola, M, Mondola, R. JWH-122 Consumption adverse effects: a case of hallucinogen persisting perception disorder five-year follow-up. J Psychoactive Drugs 2017;49(3):262–265. https://doi.org/10.1080/02791072.2017.1316431Google Scholar

Martinotti, G, Santacroce, R, Pettorruso, M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Orsolini, L, Papanti, GD, De Berardis, D, et al. The ‘endless trip’ among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 2017;8:240. https://doi.org/10.3389/fpsyt.2017.00240Google Scholar

Lev-Ran, D, Feingold, D, Goodman, C, Lerner, AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Forrester, MB, Kleinschmidt, K, Schwarz, E, Young, A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 2011;30:351–358.Google Scholar

Haden, M, Dargan, PI, Archer, JRH, et al. MDMB-CHMICA: availability, patterns of use and toxicity associated with this novel psychoactive substance. Subst Use Misuse 2017;52:223–232.Google Scholar

Westin, AA, Frost, J, Brede, WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol 2016;40:86–87.Google Scholar

Adamowicz, P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 2016;261:e5–10.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction [Internet]. EMCDDA–Europol Joint Report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), Joint Reports. Luxembourg, Publications Office of the European Union, 2016.Google Scholar

Hill, SL, Najafi, J, Dunn, M, et al.Clinical toxicity following analytically confirmed use of the synthetic cannabinoids MDMBCHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol 2016;54:638–643.Google Scholar

Angerer, V, Franz, F, Schwarze, B, et al. Reply to ‘Sudden cardiac death following use of the synthetic cannabinoid MDMBCHMICA’. J Anal Toxicol 2016;40:240–242.Google Scholar

Pacher, P, Steffens, S, Haskó, G, Schindler, TH, Kunos, G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol 2018;15(3):151–166. https://doi.org/10.1038/nrcardio.2017.130Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Canning, J, Ruha, A, Pierce, R, Torrey, M, Reinhart, S. Severe GI distress after smoking JWH-018. Clin Toxicol 2010;48:618.Google Scholar

Yen, M, Berger, RE, Roberts, J, Ganetsky, M. Middle cerebral artery stroke associated with use of synthetic cannabinoid K2. Clin Toxicol 2012;50(7):673–674.Google Scholar

Gunderson, EW, Haughey, HM, Ait-Daoud, N, et al. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus 2014;35:184–189.Google Scholar

Lapoint, J, Nelson, LS. Synthetic cannabinoids: the newest, almost illicit drug of abuse. Emerg Med 2011;43(2):26–28.Google Scholar

Ng, SK, Brust, JC, Hauser, WA, Susser, M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 1990;132:47–57.Google Scholar

Gordon, E, Devinsky, O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001;42:1266–1272.Google Scholar

Keeler, MH, Reifler, CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 1967;28:474–475.Google Scholar

Schneir, A, Baumbacher, T. Convulsions as a complication of synthetic cannabinoid use. Clin Toxicol 2011;49(6):526.Google Scholar

Hoyte, CO, Jacob, J, Monte, AA, Al-Jumaan, M, Bronstein, AC, Heard, KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012;60:435–438.Google Scholar

Bäckberg, M, Tworek, L, Beck, O, et al. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA Project. J Med Toxicol 2017;13:52–60. https://doi.org/10.1007/s13181-016-0584-2Google Scholar

Schep, LJ, Slaughter, RJ, Hudson, S, et al.Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol 2015;34:557–560.Google Scholar

Hermanns-Clausen M, Muller D, Kithinji J, et al. Acute side effects after consumption of the novel synthetic cannabinoids ABCHMINACA and MDMB-CHMICA. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 24–27 May, 2016, Madrid, Spain. Clin Toxicol 2016;54:344–519 (Abstract 17).Google Scholar

Zarifi, C, Vyas, S. Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. Perm J 2017;21:16–160.Google Scholar

Seifert, SA, Brazwell, EM, Smeltzer, C, Gibb, J, Logan, BK. Seizure and acute kidney injury associated with synthetic cannabinoid use. Clin Toxicol 2013;51(7):667.Google Scholar

Kazory, A, Aiyer, R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J 2013;6(3):330–333.Google Scholar

Bhanushali, GK, Jain, G, Fatima, H, Leisch, LJ, Thornley-Brown, D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013;8(4):523–526. https://doi.org/10.2215/CJN.05690612Google Scholar

Coca, SG, Singanamala, S, Parikh, CR. Chronic kidney disease after kidney injury: a systemic review and meta-analysis. Kid Int 2012;81:442–448.Google Scholar

Murphy, TD, Weidenbach, KN, Houten, CV, et al. Acute kidney injury associated with synthetic cannabinoid use: multiple states, 2012. Morb Mort Wkly Rep 2013;62:93–98.Google Scholar

Karass M, Chugh S, Andries G, et al. Thrombotic microangiopathy associated with synthetic cannabinoid receptor agonists. Stem Cell Investig 2017;4:43. https://doi.org/10.21037/sci.2017.05.05Google Scholar

Armstrong, F, McCurdy, MT, Heavner, MS. Synthetic cannabinoid-associated multiple organ failure: case series and literature review. Pharmacotherapy 2019;39(4):508–513. https://doi.org/10.1002/phar.2241Google Scholar

Westerbergh, J, Hulten, P. Novel synthetic cannabinoids, CRA13, JWH-015, JWH-081 and JWH-210 – detected in a case series. (Abstracts of the 2011 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 24–27 May 2011, Dubrovnik, Croatia.) Clin Toxicol 2011;49(3):199.Google Scholar

Su, M, Laskowski, L, Hoffman, RS. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 2016;34:121.e1–2. https://doi.org/10.1016/j.Ajem.2015.05.052. Epub 12 June 2015. Am J Emerg Med 2016;34(8):1690. https://doi.org/10.1016/j.ajem.2016.05.015Google Scholar

March, R, Guentert, P, Kloska-Kearney, E, et al. Utilization of extracorporeal membrane oxygenation for pulmonary toxicity caused by inhaled synthetic cannabinoid. a harbinger of future complications associated with inhaled cannabinoid products. Int J Clin Med 2020;11:53–61. https://doi.org/10.4236/ijcm.2020.112006Google Scholar

Armstrong, F, McCurdy, MT, Heavner, MS. Synthetic cannabinoid-associated multiple organ failure: case series and literature review. Pharmacotherapy 2019;39(4):508–513.Google Scholar

Armstrong, F, McCurdy, MT, Heavner, MS. Synthetic cannabinoid-associated multiple organ failure: case series and literature review. Pharmacotherapy 2019;39(4):508–513.Google Scholar

Winstock, AR, Barratt, MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013;28:390–393.Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Smith, K, Flatley, J, (eds.). Drug Misuse Declared: Findings from the 2010/11 British Crime Survey. England and Wales (Home Office Statistical Bulletin). London, Home Office, 2011.Google Scholar

Abouchedid, R, Hudson, S, Thurtle, N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an emergency department in London, UK in the first half of 2015. Clin Toxicol 2017;55:338–345.Google Scholar

Law, RK, Schier, J, Martin, C, Chang, A, Wolkin, A. Increase in reported adverse health effects related to synthetic cannabinoid use – United States, January–May 2015. Morb Mort Wkly Rep 2016;64(22).Google Scholar

Hermanns-Clausen, M, Kneisel, S, Szabo, B, Auwärter, V. Intoxications by synthetic cannabinoids – current trends. (Abstracts of the 2011 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 24–27 May 2011, Dubrovnik, Croatia.) Clin Toxicol 2011;49(3).Google Scholar

Theunissen EL, Reckweg JT, Hutten NRPW, et al. Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. Psychopharmacology 2021 (online). https://doi.org/10.1007/s00213-021-05768-0Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Glue, P, Al-Shaqsi, S, Hancock, D, Gale, C, Strong, B, Schep, L. Hospitalisation associated with use of the synthetic cannabinoid K2. NZ Med J 2013;126(1377):18–22.Google Scholar

Hobbs, M, Patel, R, Morrison, PD, Kalk, N, Stone, JM. Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: a retrospective electronic case register study. J Psychopharmacol 2020;34(6):648–653.Google Scholar

Cordeiro SK, Daro RC, Seung H, Klein-Schwartz W, Kim HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850–1861.Google Scholar

Hermanns-Clausen, M, Müller, D, Kithinji, J, et al.Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol 2018;56(6):404–411. https://doi.org/10.1080/15563650.2017.1393082Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Schwartz, MD, Trecki, J, Edison, LA, et al. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 2015;48:573–580.Google Scholar

Tyndall, JA, Gerona, R, De Portu, G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol 2015;53:950–956.Google Scholar

Bäckberg, M, Tworek, L, Beck, O, et al. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA Project. J Med Toxicol 2017;13:52–60. https://doi.org/10.1007/s13181-016-0584-2Google Scholar

Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 2016;261:e5–10.Google Scholar

Angerer, V, Franz, F, Schwarze, B, Moosmann, B, Auwarter, V. Reply to ‘Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA’. J Anal Toxicol 2016;40:240–242.Google Scholar

Westin, AA, Frost, J, Brede, WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol 2016;40:86–87.Google Scholar

Abouchedid R, Thurtle N, Yamamoto T, et al. (eds.). Analytical confirmation of the synthetic cannabinoid receptor agonists (SCRAs) present in a cohort of presentations with acute recreational drug toxicity to an Emergency Department (ED) in London, UK. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), Madrid, Spain, 2016. Clin Toxicol 2016;54(4):344–519. https://doi.org/103109/1556365020161165952Google Scholar

Abouchedid, R, Ho, JH, Hudson, S, et al.Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol 2016;12(4):396–401. https://doi.org/10.1007/s13181-016-0571-7Google Scholar

Sobolevsky, T, Prasolov, I, Rodchenkov, G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010;200:141–147.Google Scholar

Emerson, B, Durham, B, Gidden, J, Lay, JO Jr. Gas chromatography–mass spectrometry of JWH-018 metabolites in urine samples with direct comparison to analytical standards. Forensic Sci Int 2013;229(1–3):1–6. https://doi.org/10.1016/j.forsciint.2013.03.006Google Scholar

Lovett, DP, Yanes, EG, Herbelin, TW, Knoerzer, TA, Levisky, JA. Structure elucidation and identification of a common metabolite for naphthoylindole-based synthetic cannabinoids using LC-TOF and comparison to a synthetic reference standard. Forensic Sci Int 2013;226(1–3):81–87. https://doi.org/10.1016/j.forsciint.2012.12.012Google Scholar

Schneir, AB, Cullen, J, Ly, BT. ‘Spice’ girls: synthetic cannabinoid intoxication. J Emerg Med 2011;40(3):296–299. https://doi.org/10.1016/j.jemermed.2010.10.014Google Scholar

Coppola M, , Mondola, R. JWH-122 Consumption adverse effects: a case of hallucinogen persisting perception disorder five-year follow-up. J Psychoactive Drugs 2017;49(3):262–265. https://doi.org/10.1080/02791072.2017.1316431Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Zhao A, Tan M, Maung A, Salifu M, Mallappallil M. Case rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Rep Nephrol 2015;2015:235982. https://doi.org/doi.org/10.1155/2015/235982Google Scholar

Rodgman, C, Kinzie, E, Leimbach, E. Bad mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis. Am J Emerg Med 2011;29:232.Google Scholar

Cordeiro, SK, Daro, RC, Seung, H, Klein-Schwartz, W, Kim, HK. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Addiction 2018;113:1850– 1861.Google Scholar

Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology 2017 (online). https://doi.org/10.1016/j.neuropharm.2017.10.017Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Castaneto, MS, Gorelick, DA, Desrosiers, NA, et al. 2014. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12e41.Google Scholar

Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology 2017 (online). https://doi.org/10.1016/j.neuropharm.2017.10.017Google Scholar

Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology 2017 (online). https://doi.org/10.1016/j.neuropharm.2017.10.017Google Scholar

Hermanns-Clausen, M, Kneisel, S, Szabo, B, Auwärter, V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108:534–544.Google Scholar

Tait, RJ, Caldicott, D, Mountain, D, Hill, SL, Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2015;15:1–13.Google Scholar

Monte, AA, Bronstein, AC, Dahze, JC, et al. Supplementary appendix to an outbreak of exposure to a novel synthetic cannabinoid. New Engl J Med 2014;370(4):389–390. Available at: www.nejm.org/doi/suppl/10.1056/NEJMc1313655/suppl_file/nejmc1313655_appendix.pdf [last accessed 28 March 2022].Google Scholar

Bonaccorso S, Metastasio A, Ricciardi A, et al. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sci 2018;8:133. https://doi.org/10.3390/brainsci8070133Google Scholar

Zimmermann, US, Winkelmann, PR, Pilhatsch, M, Nees, JA, Spanagel, R, Schulz, K. Withdrawal phenomena and dependence syndrome after the consumption of ‘Spice Gold’. Dtsch Arztebl Int 2009;106:464–467.Google Scholar

Atwood, BK, Huffman, J, Straiker, A, Mackie, K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010;160(3):585–593.Google Scholar

Macfarlane, V, Christie, G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34:147–153.Google Scholar

Rodgman, CJ, Verrico, CD, Worthy, RB, Lewis, EE. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS 2014;16:4.Google Scholar

Nacca, N, Vatti, D, Sullivan, R, Sud, P, Su, M, Marraffa, J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7(4):296–298. https://doi.org/10.1097/ADM.0b013e31828e1881Google Scholar

Cooper, ZD, Haney, M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 2008;13:188–195.Google Scholar

Macfarlane, V, Christie, G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34(2):147–153.Google Scholar

Barratt, MJ, Cakic, V, Lenton, S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013;32(2):141–146. https://doi.org/10.1111/j.1465-3362.2012.00519.xGoogle Scholar

Zimmermann, US, Winkelmann, PR, Pilhatsch, M, Nees, JA, Spanagel, R, Schulz, K. Withdrawal phenomena and dependence syndrome after the consumption of ‘Spice Gold’. Dtsch Arztebl Int 2009;106(27):464–467. https://doi.org/10.3238/arztebl.2009.0464Google Scholar

Atwood, BK, Huffman, J, Straiker, A, Mackie, K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010;160(3):585–593.Google Scholar

Van Hout, MC, Hearne, E. User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes Int J Ment Health Addiction 2017;15: 565. https://doi.org/10.1007/s11469-016-9650-xGoogle Scholar

Cooper, ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18:52. https://doi.org/10.1007/s11920-016-0694-1Google Scholar

Cooper, ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18:52. https://doi.org/10.1007/s11920-016-0694-1Google Scholar

Castaneto, MS, Gorelick, DA, Desrosiers, NA, et al.Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12e41.Google Scholar

Macfarlane, V, Christie, G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34:147–153.Google Scholar

Lin, CY, Wheelock, AM, Morin, D, et al. Toxicity and metabolism of methylnaphthalenes: comparison with naphthalene and 1-nitronaphthalene. Toxicology 2009;260(1–3):16–27. https://doi.org/10.1016/j.tox.2009.03.002Google Scholar

Hopkins, CY, Gilchrist, BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 2013;45(4):544–546.Google Scholar

Armstrong, F, McCurdy, MT, Heavner, MS. Synthetic cannabinoid‐associated multiple organ failure: case series and literature review. Pharmacotherapy 2019;39:508–513.Google Scholar

Alhadi, S, Tiwari, A, Vohra, R, Gerona, R, Acharya, J, Bilello, K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 2013;9(2):199–206.Google Scholar

Cooper, ZD, Haney, M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 2008;13:188–195.Google Scholar

Rodgman, CJ, Verrico, CD, Worthy, RB, Lewis, EE. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS 2014;16:4.Google Scholar

Macfarlane, V, Christie, G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34:147–153.Google Scholar

Nacca, N, Vatti, D, Sullivan, R, Sud, P, Su, M, Marraffa, J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7:296–298.Google Scholar

Sweeney, B, Talebi, S, Toro, D, et al.Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 2016;34(1):121– e1 .Google Scholar

Oluwabusi, OO, Lobach, L, Akhtar, U, Youngman, B, Ambrosini, PJ. Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol 2012;22:393–395.Google Scholar

Ustundag MF, Ozhan IE, Yucel A, Ozcan H. Synthetic cannabis-induced mania. Case Rep Psychiatry 2015;2015:310930.Google Scholar

Alvarez, Y, Pérez-Mañá, C, Torrens, M, Farré, M. Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat 2013;45(1):1–10. https://doi.org/10.1016/j.jsat.2012.12.013CrossRefGoogle Scholar

Seeman, P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27–38.Google Scholar

Macfarlane, V, Christie, G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34:147–153.Google Scholar

Nacca, N, Vatti, D, Sullivan, R, Sud, P, Su, M, Marraffa, J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7:296–298.Google Scholar

Rodgman, CJ, Verrico, CD, Worthy, RB, Lewis, EE. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS 2014;16:4.Google Scholar

Hermanns-Clausen, M, Kneisel, S, Szabo, B, Auwärter, V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108:534–544.Google Scholar